Improving quality of life in COPD
Inhaling a long-acting beta-agonist (LABA) or a long-acting anticholinergic drug improves lung function in COPD. The choice of therapy could be influenced if some of these drugs also improved patient quality of life. A European group reviewed 21 trials of LABA involving 12,213 patients. While eformoterol, indacaterol and salmeterol generally improved the quality of life, the benefit was not always significant.
Long-acting anticholinergic drugs were studied in 23 trials involving 22,653 patients. Glycopyrronium was only assessed in two trials and aclidinium in three, so most of the trials studied inhaled